Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1917 2
1954 1
1965 1
1974 1
1979 1
1981 1
1983 4
1984 1
1987 2
1988 1
1989 1
1990 1
1991 2
1992 3
1993 2
1994 1
1995 4
1996 1
1997 4
1998 3
1999 2
2000 8
2001 3
2002 3
2003 3
2004 8
2005 1
2006 1
2007 1
2008 1
2009 2
2010 5
2011 4
2012 2
2013 10
2014 5
2015 5
2016 4
2017 1
2018 3
2019 7
2020 13
2021 11
2022 15
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

147 results

Results by year

Filters applied: . Clear all
Page 1
Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.
Neilan TG, Quinaglia T, Onoue T, Mahmood SS, Drobni ZD, Gilman HK, Smith A, Heemelaar JC, Brahmbhatt P, Ho JS, Sama S, Svoboda J, Neuberg DS, Abramson JS, Hochberg EP, Barnes JA, Armand P, Jacobsen ED, Jacobson CA, Kim AI, Soumerai JD, Han Y, Friedman RS, Lacasce AS, Ky B, Landsburg D, Nasta S, Kwong RY, Jerosch-Herold M, Redd RA, Hua L, Januzzi JL, Asnani A, Mousavi N, Scherrer-Crosbie M. Neilan TG, et al. Among authors: barnes ja. JAMA. 2023 Aug 8;330(6):528-536. doi: 10.1001/jama.2023.11887. JAMA. 2023. PMID: 37552303 Free PMC article. Clinical Trial.
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, Barnes JA, O'Brien SM, Chávez JC, Duell J, Rosenwald A, Crombie JL, Ufkin M, Li J, Zhu M, Ambati SR, Chaudhry A, Lowy I, Topp MS. Bannerji R, et al. Among authors: barnes ja. Lancet Haematol. 2022 May;9(5):e327-e339. doi: 10.1016/S2352-3026(22)00072-2. Epub 2022 Apr 1. Lancet Haematol. 2022. PMID: 35366963 Free PMC article. Clinical Trial.
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.
Soumerai JD, Mato AR, Dogan A, Seshan VE, Joffe E, Flaherty K, Carter J, Hochberg E, Barnes JA, Hamilton AM, Abramson JS, Batlevi CL, Matasar MJ, Noy A, Owens CN, Palomba ML, Kumar A, Takvorian T, Ni A, Choma M, Friedman C, Chadha P, Simkins E, Ruiters J, Sechio S, Portman D, Ramos L, Nolet N, Mahajan N, Martignetti R, Mi J, Scorsune K, Lynch J, McGree B, Hughes S, Grieve C, Roeker LE, Thompson M, Johnson PC, Roshal M, Huang J, Biondo J, Wu Q, Jacob A, Abdel-Wahab O, Zelenetz AD. Soumerai JD, et al. Among authors: barnes ja. Lancet Haematol. 2021 Dec;8(12):e879-e890. doi: 10.1016/S2352-3026(21)00307-0. Lancet Haematol. 2021. PMID: 34826411 Free PMC article. Clinical Trial.
Endoscopic Management of Early Esophageal Cancer.
Barnes JA, Willingham FF. Barnes JA, et al. J Clin Gastroenterol. 2015 Sep;49(8):638-46. doi: 10.1097/MCG.0000000000000353. J Clin Gastroenterol. 2015. PMID: 26125458 Review.
Introduction: Health, Well-Being, and Ability in Archaeology.
Camp SL, Barnes JA, Surface-Evans S. Camp SL, et al. Among authors: barnes ja. Int J Hist Archaeol. 2023;27(1):1-16. doi: 10.1007/s10761-021-00645-0. Epub 2022 Jan 8. Int J Hist Archaeol. 2023. PMID: 35035208 Free PMC article.
Health Issues Among Nepalese Youth: A Literature Review.
Stoll V, Edwin N, Dahal K, Barnes JA, Pfautsch M, Maharjan L, Blavo C. Stoll V, et al. Among authors: barnes ja. Cureus. 2023 Sep 12;15(9):e45108. doi: 10.7759/cureus.45108. eCollection 2023 Sep. Cureus. 2023. PMID: 37842493 Free PMC article. Review.
Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells.
Karschnia P, Arrillaga-Romany IC, Eichler A, Forst DA, Gerstner E, Jordan JT, Ly I, Plotkin SR, Wang N, Martinez-Lage M, Winter SF, Tonn JC, Rejeski K, von Baumgarten L, Cahill DP, Nahed BV, Shankar GM, Abramson JS, Barnes JA, El-Jawahri A, Hochberg EP, Johnson PC, Soumerai JD, Takvorian RW, Chen YB, Frigault MJ, Dietrich J. Karschnia P, et al. Among authors: barnes ja. Neuro Oncol. 2023 Dec 8;25(12):2239-2249. doi: 10.1093/neuonc/noad118. Neuro Oncol. 2023. PMID: 37402650 Free PMC article.
PEST sequences in calmodulin-binding proteins.
Barnes JA, Gomes AV. Barnes JA, et al. Mol Cell Biochem. 1995 Aug-Sep;149-150:17-27. doi: 10.1007/BF01076559. Mol Cell Biochem. 1995. PMID: 8569726 Review.
Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma.
Abramson JS, Bengston E, Redd R, Barnes JA, Takvorian T, Sokol L, Lansigan F, Armand P, Shah B, Jacobsen E, Martignetti R, Turba E, Metzler S, Patterson V, LaCasce AS, Bello CM. Abramson JS, et al. Among authors: barnes ja. Blood Adv. 2023 Apr 11;7(7):1130-1136. doi: 10.1182/bloodadvances.2022008420. Blood Adv. 2023. PMID: 36053786 Free PMC article. Clinical Trial.
147 results